Skip to main content

Article Category

News

Article available in the folowing languages:

Call for new partner in the field of miniaturization

The FP-7 BLUEPRINT consortium, focussed on the epigenome of haematopoietic cells, is seeking a new partner in the field of miniaturization.

BLUEPRINT is a High Impact Project receiving close to 30 million euro funding from the EU. Forty-two leading European universities, research institutes and industry entrepreneurs participate in this consortium which aims to further the understanding of how genes are activated or repressed in both healthy and diseased human cells. BLUEPRINT focuses on distinct types of haematopoietic cells from healthy individuals and on their malignant leukaemic counterparts. BLUEPRINT will generate at least 100 reference epigenomes and study them to advance and exploit knowledge of the underlying biological processes and mechanisms in health and disease. Reference epigenomes are being generated by state-of-the-art technologies from highly purified cells for a comprehensive set of epigenetic marks in accordance with quality standards set by the International Human Epigenome Consortium (IHEC). Chromatin-Immunoprecipitation is the key experimental approach to locate histone modifications and transcription factors in the genome, yet for robust and automatized detection this assay requires large numbers of cells. A key objective of BLUEPRINT is to reduce the number of cells required as input for one ChIP-seq profile aiming at less then 5000 cells per profile. This is particularly important for the analysis of cells that are rare, e.g. the HSC or clinical samples of cells that are obtained by small volume needle biopsies, e.g. in case of solid organ cancers. We are looking for a novel academic or SME partner to strengthen Work Package 13 ‘Technology optimization for microscale application’. The new BLUEPRINT partner should have an operational analysis pipeline or will have such a pipeline up and running by the end of 2013. To this end, we expect applicants to have proof of concept data. The analysis pipeline should encompass pre- and post-chip sample preparation, the end product being a library ready for Illumina Next Gen Sequencing. Further information about the call and guidelines for application (deadline January 31, 2013) can be found on the project website: http://www.blueprint-epigenome.eu/

Countries

Austria, Belgium, Bulgaria, Cyprus, Czechia, Germany, Denmark, Estonia, Greece, Spain, Finland, France, Hungary, Ireland, Italy, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, United Kingdom